PHARMA Duro 30 (30pc)
R650,00
DUROMINE may appropriately be initiated in overweight patients with a lower BMI when risk of
morbidity from other medical conditions is increased. P
Guarantee safe & secure checkout
On all order
Description
DUROMINE may appropriately be initiated in overweight patients with a lower BMI when risk of
morbidity from other medical conditions is increased.
Quick Comparison
| PHARMA Duro 30 (30pc) remove | NOVA Meno-Pause remove | NOVA Melano Glow remove | BP Tirze 30 remove | BP Semag 6 remove | HDL Semag 10 remove | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PHARMA Duro 30 (30pc) remove | NOVA Meno-Pause remove | NOVA Melano Glow remove | BP Tirze 30 remove | BP Semag 6 remove | HDL Semag 10 remove | ||||||||||
| Image | |  | | | | | ||||||||||
| SKU | IN_LK-22 | IN_LK-21 | IN_LK-6 | IN_LK-5 | IN_LK-11 | |||||||||||
| Rating | ||||||||||||||||
| Price | R650,00 | R1 500,00 | R1 100,00 | R2 800,00 | R2 500,00 | R1 450,00 | ||||||||||
| Stock | ||||||||||||||||
| Weight | N/A | N/A | N/A | N/A | N/A | N/A | ||||||||||
| Dimensions | N/A | N/A | N/A | N/A | N/A | N/A | ||||||||||
| Additional information |
|
|
|
|
| |||||||||||
| Description | DUROMINE may appropriately be initiated in overweight patients with a lower BMI when risk of morbidity from other medical conditions is increased. P | Meno-Pause combines Ipamorelin and Sermorelin, two peptides that stimulate natural growth hormone production. This combination is designed to support women during menopause by improving energy, sleep, skin health, and overall wellbeing. | Melano Glow by Peptide Pen brings you skin radiance, elasticity, and natural pigmentation—all from the inside out. Powered by Melanotan II, this anti-aging peptide stimulates melanin production, enhancing your skin tone and UV resilience while promoting collagen health and longevity. | BodyPharm (BP) Tirzepatide 30mg is a high-concentration research compound designed to mimic the action of hormones that manage blood sugar and appetite, primarily marketed in South Africa for laboratory use. [1, 2] |
| Semaglutide activates the GLP-1 (glucagon-like peptide-1) receptor, producing multiple downstream effects: enhanced insulin secretion in response to meals, suppressed glucagon output, delayed gastric emptying, and reduced appetite signals. | ||||||||||
| Add to cart |
